Search

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

25.68 -0.54

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

25.53

Massimo

25.72

Metriche Chiave

By Trading Economics

Entrata

191K

-51M

Vendite

6.7M

106M

EPS

-0.46

Margine di Profitto

-47.808

Dipendenti

1,784

EBITDA

-2.1M

-46M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+53.05% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

737M

2.8B

Apertura precedente

26.22

Chiusura precedente

25.68

Notizie sul Sentiment di mercato

By Acuity

38%

62%

77 / 339 Classifica in Healthcare

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 set 2026, 23:41 UTC

News

Iovance Biotherapeutics granted inducement stock options for 179.75k shares to new employees, contributing to a modest decline in after-market hours.

18 set 2026, 23:31 UTC

News

BlackRock Inc. shares are modestly lower in after-market trading amid heightened legal concerns as the DOJ considers intervention in an antitrust lawsuit against the company.

18 set 2026, 23:26 UTC

News

State Street Corp declines in after-market trading as the U.S. Department of Justice considers intervention in a state antitrust lawsuit regarding energy price inflation.

18 set 2026, 23:16 UTC

News

Union Pacific Corp's stock is trading higher in after-market hours following UBS's upgrade to Buy and a price target increase to $339, citing expected cargo growth.

18 set 2026, 23:11 UTC

News

AutoNation Inc has been downgraded from Buy to Hold amid industry challenges, yet the stock is rising in after-market trading as the broader market advances.

18 set 2026, 23:11 UTC

News

Leidos Holdings Inc. has secured an $85 million contract from the U.S. Department of War for aerospace systems design, with shares rising in after-market trading.

18 set 2026, 23:06 UTC

News

AbbVie Inc. is experiencing a slight decline in after-market trading, positioned near the lower end of its recent trading range despite promising myeloma study results.

18 set 2026, 23:06 UTC

News

Boeing is in talks with NASA to expand its Starliner program, potentially adding ten or more flights, as the stock moves higher in after-hours trading.

18 set 2026, 23:06 UTC

News

Chevron Corp has declined in after-market trading, despite Goldman Sachs raising its price target to $240 and Piper Sandler setting an even higher target of $243.

18 set 2026, 23:06 UTC

News

Okta Inc appointed Helen Riley to its board, enhancing leadership as shares rise in after-market trading, aligning with a broader market advance.

18 set 2026, 23:06 UTC

News
Social Media

Nike shares are advancing in after-market hours despite recent challenges, including a significant decline and hitting a 12-year low.

18 set 2026, 23:06 UTC

News

General Motors Co is advancing in after-market trading following its decision to reinstate Apple’s CarPlay and Android Auto in its vehicles.

18 set 2026, 23:06 UTC

News

Medtronic PLC raised its fiscal 2027 profit forecast and reported first-quarter revenue of $9.756 billion, exceeding expectations, in after-market trading.

18 set 2026, 23:06 UTC

News

RTX Corp's backlog hit a record $289 billion, with the stock advancing in after-market trading, despite remaining below its 20-day moving average.

18 set 2026, 23:06 UTC

News

Celsius Holdings Inc shares are higher in after-market trading, continuing a positive trend despite ongoing legal scrutiny over its Alani Nu product line.

18 set 2026, 23:01 UTC

News
Social Media

Northrop Grumman targets $10 billion in annual international sales by 2031, while shares trade lower in after-market hours.

18 set 2026, 23:01 UTC

News

Kimberly-Clark Corp plans to divest assets related to its $40 billion Kenvue acquisition to address EU antitrust concerns, with shares modestly higher in after-market trading.

18 set 2026, 23:01 UTC

Social Media
News

Accenture PLC announced a $1 billion partnership with Anthropic to enhance AI evaluation capabilities, leading to a sharp advance in shares during after-market hours.

18 set 2026, 23:01 UTC

News

Bitcoin is sharply higher, trading well above its previous close amid a rally in the cryptocurrency market, driven by strong investor sentiment and recent Fed announcements.

18 set 2026, 23:01 UTC

News

Ethereum is advancing sharply, continuing its upward trajectory alongside a broader cryptocurrency rally, despite earlier pulling back from a session high.

18 set 2026, 23:01 UTC

News

Ethereum is advancing sharply, remaining significantly higher since Thursday's close, as the cryptocurrency market rallies alongside Bitcoin surpassing $81k.

18 set 2026, 23:01 UTC

News

Sharply higher amid strong investor sentiment and Fed announcements.

18 set 2026, 23:01 UTC

News
Social Media

Wendy's Co shares are trading modestly higher in after-market hours despite concerns over Meritage Hospitality Group's Chapter 11 bankruptcy filing affecting 314 locations.

18 set 2026, 22:51 UTC

News

Lockheed Martin Corp receives an $871.2 million contract modification for F-35 support, contributing to a modest after-market hours gain.

18 set 2026, 22:51 UTC

News

Hf Foods Group Inc. has terminated its $100 million at-the-market equity offering program, leading to a sharp decline in after-market trading.

18 set 2026, 22:01 UTC

News

Simply Good Foods Co is facing a securities fraud class action lawsuit, contributing to a modest decline in after-market trading following concerns over OWYN's sales performance.

18 set 2026, 21:41 UTC

News

Amneal Pharmaceuticals received FDA approval for its lanreotide injection, launching the product immediately, driving shares higher in after-market hours.

18 set 2026, 21:03 UTC

Macro News
News
Macro Event

The Bank of Japan raised its key interest rate to 1.25%, boosting the USD/JPY pair, which is trading higher above Thursday's close.

18 set 2026, 21:01 UTC

News

Navient Corp is seeing a modest increase in after-market trading, reflecting routine performance and placing the price around the middle of its one-month range.

18 set 2026, 21:01 UTC

News
Macro Event
Correlated Moves

The Bank of Japan raised its key short-term interest rate to 1.25%, causing GBP/JPY to trade modestly higher, though still below its 20-day moving average.

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

53.05% in crescita

Previsioni per 12 mesi

Media 39.333 USD  53.05%

Alto 45 USD

Basso 36 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

77 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.